Five Prime Therapeutics, Inc. (FPRX)
(Delayed Data from NSDQ)
$11.55 USD
+0.51 (4.62%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.54 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[FPRX]
Reports for Purchase
Showing records 1 - 20 ( 89 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
4Q20 - Reports FY 2020. Acquisition by Amgen Expected to Close in Q221.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL: Amgen Acquires FPRX for $1.9B
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Amgen Pays $1.9B for a Gastric Cancer Asset, but Little-to-Nothing for the Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
You Are Invited to Our Virtual 33rd Annual ROTH Conference on March 15-17, 2021
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
FIGHT Data at ASCO-GI; Opportunity Likely to Extend Past Gastric
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
FIGHT Posts Knockout Topline Data; Raising PT to $28
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R